Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Cognition Therapeutics, Inc. (CGTX) had Consolidated Net Income/Loss of $-4.57M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-4.57M |
|
-- |
|
-- |
|
$8.82M |
|
$-8.82M |
|
$4.25M |
|
$-4.57M |
|
$-4.57M |
|
$-4.57M |
|
$-4.57M |
|
|
Consolidated Net Income/Loss |
$-4.57M |
$-4.57M |
|
$-8.82M |
|
$-8.75M |
|
89.19M |
|
89.19M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$35.81M |
|
$0.08M |
|
$0.33M |
|
$36.14M |
|
$6.05M |
|
-- |
|
$0.18M |
|
$6.23M |
|
$29.91M |
|
$29.91M |
|
$29.91M |
|
89.35M |
|
| Cash Flow Statement Financials | |
$-5.54M |
|
-- |
|
$-0.23M |
|
$37.00M |
|
$31.23M |
|
$-5.78M |
|
$0.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.92 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.28% |
|
-15.28% |
|
-12.65% |
|
-15.28% |
|
$0.33 |
|
$-0.06 |
|
$-0.06 |
|